MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'enrollment'. Sat, 03 Sep 2011 03:35:58 +0100 http://www.medworm.com/index.php?rid=5069825&cid=t_450128_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FRqwvmj9MSCs%2F As drugmakers scramble to replenish their pipelines, they are encountering all sorts of difficulties, including rising costs for clinical trials. And this is happening across all phases. Why? There is increasing competition for trial sites and clinical research organizations that can yield reliable, high quality data, according to a recent survey. And so, 32 percent of those surveyed pointed to higher costs for enrolling patients and 25 percent cited vendor fees. Expenses for recruiting trial sites was named by 14 percent, followed by 12 percent who fingered technology costs, according to Cutting Edge Information, which surveyed 21 drugmakers, 12 biotechs, nine device makers and 23 contract research organizations. Meanwhile, staffing for drug development is rising. For instance, Phase IV ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5069825 Tue, 26 Jul 2011 14:39:41 +0100 5069825 http://www.medworm.com/index.php?rid=4976202&cid=t_450128_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FoTKlwddQleA%2F Recruiting patients for clinical trials is increasingly tricky, especially in the US, where many people remain uninterested in participation. In many cases, drugmakers are also hard-pressed to find ‘treatment naive’ patients - those who are not on other meds. The Internet, however, has opened up a new source of potentially willing participants, since so many seek health info online. But how likely are they to enroll and what might prompt them to do so? A recent survey of 179 adults, who were queried through postings in online health communities, finds that 84 percent have never participated in a trial. But of those, four of five would do so. And the reasons cited most often: 22 percent would enroll if a drug offered a cure and 21 percent if they could help find a cure. Online o... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4976202 Tue, 28 Jun 2011 16:22:57 +0100 4976202 http://www.medworm.com/index.php?rid=4759043&cid=t_450128_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FF7d0dGHppWA%2F Top of the morning to you. Gray skies are hovering over the Pharmalot corporate campus, but our spirits remain sunny. And why not? This inspires us to trot out one of our favorite sayings, courtesy of the morning mayor: ‘Every brand new day should be unwrapped like a precious gift.’ So while you tug on the ribbon, here are a few items to get you started. Have a great day, everyone, and smile… Merck To Buy Back Up To $5 Billion In Stock (Reuters) Teva Resumes Manufacturing At California Site (Orange County Business Journal) J&J Agrees To Buy Synthes For $21.3 Billion (Bloomberg News) Supreme Court Skeptical About Vermont Data Mining Law (Bellingham Herald) Lupin May Wait To Sell Birth Control Pills In The US (Bloomberg News) Merck And Biogen Expand Facilities In North... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4759043 Wed, 27 Apr 2011 11:54:02 +0100 4759043 http://www.medworm.com/index.php?rid=4003295&cid=t_450128_109_f&fid=34761&url=http%3A%2F%2Ffeeds.feedblitz.com%2F%7E%2F20972647%2F0%2Fneuromarketing%7EThe-Case-FOR-College-Sports.htm Recently, Newsweek ran a big article titled The Case Against College Athletic Recruiting, with the sensational subtitle claiming that U.S. universities are “misappropriating resources” on sports. Accusing some of the nation’s most revered institutions of financial malfeasance is no small thing. But are colleges really squandering the money they spend on athletics? Perhaps in some [...] CommentsProbably the most oft-cited justification for investing in ... by Roger DooleyVery interesting piece on so many levels. I, too, have pondered ... by Nadine Bendycki (Source: Neuromarketing) Neuromarketing blogs http://www.medworm.com/rss/comments.php?id=4003295 Mon, 27 Sep 2010 11:57:59 +0100 4003295 http://www.medworm.com/index.php?rid=3635727&cid=t_450128_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FcWvLlDzjCNU%2F By Andrew J. CoulsonThat’s the topic of a commentary I just wrote at BigGovernment.com, tied to recent efforts to prop up public school employment with another $23 billion bailout. I won’t repeat the text of that post here, but thought the two charts bear repeating. The first shows that employment has grown 10 times faster than enrollment over the past 40 years. The second chart shows how the total cost of sending a single child through the public school system has changed over the years, along with trends in student achievement. (Source: Cato-at-liberty) Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3635727 Mon, 07 Jun 2010 12:28:31 +0100 3635727 http://www.medworm.com/index.php?rid=3560496&cid=t_450128_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fas95V6glgzI%2F Containing drug development costs and speeding compounds through the pipeline is always a big issue, but clinical trials are becoming more expensive anyway. Why? One answer is the increasing complexity of the studies - the number of procedures for each clinical trial rose 49 percent from the 2000 to 2003 period to the 2004 to 2007 timeframe, and the total effort per protocal jumped 54 percent. For instance, the average number of eligibility criteria used to screen volunteers rose 58 percent, which contributed to a 21 percent decline in volunteers enrolling in trials. But the larger number of procedures per protocol dissuades volunteers from completing trials - retention rates dropped 230 percent, according to the Tufts Centers for the Study of Drug Development, which reviewed data from 8,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3560496 Thu, 13 May 2010 15:15:35 +0100 3560496 http://www.medworm.com/index.php?rid=3318378&cid=t_450128_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FkWx3DqwyBI4%2F By Alan ReynoldsSen. Jim Bunning (R., Ky.) blocked “extended” unemployment benefits beyond their scheduled expiration on February 27. That thwarted bill would also have put off, again, a scheduled 21 percent cut in Medicare payments to physicians. Democrats were outraged. But why? Bunning just wanted to use leftover “stimulus” money to pay for the benefits. Why not? Such transfer payments accounted for over 80 percent of stimulus spending last year. Besides, as Federal Reserve policymakers noted, the evidence is overwhelming (see here and here) that extending unemployment benefits from six months to nearly two years has raised the unemployment rate by a percentage point or two. I’ve waited since 1991 for someone to prove I’m wrong about that. Nobody has, because nobody can. If ... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3318378 Sat, 27 Feb 2010 22:39:00 +0100 3318378